If you would like to submit a blog post for consideration, please email admin@healthcert.com

Dermatology Research Review

In this dermatology research review: A phase two trial from a recent issue of N Engl J Med reports that selective IL-23 blockade with risankizumab provides better clinical responses than ustekinumab for the treatment of moderate-to-severe plaque psoriasis. Four other papers also focus on psoriasis, including a meta-analysis of the risk of major adverse CV events associated with the use of biological agents, the increased risk of avascular necrosis, and an analysis of data from the UNCOVER-1 and UNCOVER-2 trials comparing outcomes for patients treated with ixekizumab who continued treatment with those who withdrew then restarted treatment.

Featured in this issue:

  • Risankizumab vs. ustekinumab in plaque psoriasis
  • Association of PD-L1 expression in BCC with number of treatment modalities
  • Oncogene mutations in cetuximab-treated advanced cutaneous SCC
  • Major CV event risk with biologicals for psoriasis
  • Genital melanosis in men and women
  • Avascular necrosis risk increased in psoriasis
  • Silk textile with antimicrobial for acne vulgaris on the back
  • Bacterial biofilm in hidradenitis suppurativa lesions
  • Continuous vs. interrupted ixekizumab for psoriasis
  • Clinical markers of vitiligo activity

Click here to download the full paper 

Interested in General Dermatology?

The HealthCert Professional Diploma of General Dermatology will teach you how to manage all major dermatological conditions in primary care. The courses are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The program is delivered online.

Clinical Procedures Certificate Courses in Australia

Leave a Reply

Your email address will not be published. Required fields are marked *